---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-106461"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2024-10-07T23:59:59+00:00"
generated_at: "2026-05-30T19:21:36.984948+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Apitegromab meets Phase 3 primary endpoint in SMA; Scholar Rock plans BLA/MAA filing Q1 2025

## Summary
- Primary endpoint met: apitegromab improved HFMSE vs placebo (mean diff 1.8 points, p=0.0192) in patients ages 2-12.
- 30.4% of apitegromab patients had >3 point HFMSE improvement vs 12.5% on placebo.
- Benefit observed from first time point at 8 weeks, sustained to 52 weeks.
- Safety profile consistent with prior trials; no SAEs related to apitegromab.
- Company plans to submit BLA to FDA and MAA to EMA in Q1 2025.

## SEC filing metadata
- accession: 0001104659-24-106461
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2024-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000110465924106461/0001104659-24-106461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000110465924106461/tm2425688d7_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-106461
- JSON: https://secwatch.observer/filing/0001104659-24-106461.json
- Plain text: https://secwatch.observer/filing/0001104659-24-106461.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.